MannKind to acquire V-Go device from Zealand Pharma for $10M plus up to $17M in inventory and milestones

MANNKIND CORP

Purchase price: $10.0M plus book value of finished goods inventory (not to exceed $7.0M) and up to $10.0M in sales-based milestone payments.
Milestone payments triggered when annual V-Go revenue reaches thresholds between $40M and $100M.
Company will assume a facility lease in Marlborough, MA with monthly payments of $28,895, expiring Feb 2026.
Up to 40 current and former Zealand employees to be offered positions, including field sales and supply chain roles.
Closing expected in May 2022 subject to satisfaction of customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.